在5月24日结束的中国医药产业跨世纪发展研讨会上,有关专家提出我国医药产业目前面对外资企业竞争、市场趋于饱和、医疗保险制度改革等方面的挑战,形势严峻。1978～1998年间,我国医药行业年均增长18％,高出同期全国工业年均增长12.6％的速度,居全国各行业之首。但与国际先进国家相比仍有很大差距,1998年全国市场年销售总额少于美国默克公司一家销售额。目前,我国医药产业的发展遇到困境,表现在:①面对高度竞争的时代,国内注册的合资企业已达1240家。其中世界上25强大药厂已有20家在我国建立合资企业,其带着国际化资金、产品、技术、营销手段,成为我国 At the seminar on cross-century development of China’s pharmaceutical industry that ended on May 24, relevant experts proposed that China’s pharmaceutical industry is currently faced with challenges from foreign-funded enterprises, market saturation, and reform of the medical insurance system. The situation is grave. Between 1978 and 1998, China’s pharmaceutical industry grew at an average annual rate of 18%, which was higher than the average annual industrial growth rate of 12.6% in the same period, ranking the first among all industries in the country. However, there is still a big gap compared with the international advanced countries. In 1998, the total annual sales of the national market was less than that of the Merck Company. At present, the development of the pharmaceutical industry in China is facing difficulties. It is reflected in the following aspects: 1 In the era of highly competitive competition, there are 1,240 domestic joint ventures registered. Among them, 20 of the world’s 25 most powerful drug companies have established joint ventures in China, and they have become China’s international funds, products, technologies, and marketing methods.